In an exciting development for the infection control sphere, Governor Kathy Hochul announced the establishment of a pioneering pharmaceutical operation in New Windsor, Orange County – Garonit Pharmaceutical, Inc. The global manufacturer of healthcare solutions and crucial antiseptic products is set to erect a leading-edge, 200,000 square-foot facility. This groundbreaking investment of $46.1 million will see the edifice become the leading producer worldwide of chlorhexidine gluconate, an antiseptic substance of critical importance for surgical disinfection and infection control in hospitals across the globe.
Showing substantial support, the state of New York is allocating $3.8 million in backing for this monumental project, which encompasses up to $3.5 million from the Excelsior Jobs Program and a Mid-Hudson Regional Economic Development Council capital grant of $300,000. This significant move marks a key milestone in New York’s strategy to expand domestic pharmaceutical manufacturing and accentuate the growth of its life sciences sector.
Governor Hochul’s insights on New York’s strategic position in terms of reshoring pharmaceutical production, reinforcing supply chains and the creation of premier jobs were highlighted as part of this announcement. The establishment of this facility in Orange County is a testament to the state’s progress in these areas, according to Governor Hochul. With this move, New York not only bolsters the production of vital antiseptic products employed in clinical and hospital settings globally but also reasserts its position as a frontrunner in life sciences.
Empire State Development’s President, Hope Knight, stressed the confidence this move illustrates that global companies have in New York’s innovation ecosystem, infrastructure, and workforce. The strategic position of the Mid-Hudson region, its strong infrastructure, alongside proximity to leading transportation networks, make it an ideal location for progressive manufacturing operations. The promising project is expected to pave the way for robust economic gains and the region’s sustained growth in the pharmaceutical sector.